Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Krazati is a prescription RAS GTPase inhibitor containing adagrasib. Its current U.S. indication is for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, confirmed by an FDA-approved test, after at least one prior systemic therapy. The former colorectal cancer indication with cetuximab was withdrawn on September 1, 2026.
read more about krazati ...Adagrasib irreversibly binds to the mutant cysteine in KRAS G12C and locks the altered KRAS protein in an inactive state. This blocks downstream signaling involved in growth and survival of susceptible tumor cells.
Krazati is currently used as a single agent in adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer after at least one prior systemic treatment. Patient selection is based on an FDA-approved test for the KRAS G12C mutation.
The recommended dose is 600 mg by mouth twice daily until disease progression or unacceptable toxicity. Tablets can be taken with or without food and are swallowed whole. If a dose is missed by more than four hours, it is skipped rather than taken late.
Serious concerns include gastrointestinal reactions, QTc interval prolongation, hepatotoxicity, and interstitial lung disease or pneumonitis. Electrocardiograms, electrolytes, and liver tests are monitored in patients according to clinical risk and current labeling.
Krazati currently treats selected KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults after prior systemic therapy.
The recommended dose is 600 mg twice daily with or without food.
No. FDA lists the former accelerated approval of Krazati with cetuximab for colorectal cancer as withdrawn on September 1, 2026.
Yes. Krazati can prolong the QTc interval, so electrocardiograms and electrolytes are monitored in patients at risk.
Adagrasib. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a623003.html. Date Accessed October 8, 2026.
Adagrasib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/138611145. Date Accessed October 8, 2026.
DailyMed - KRAZATI (adagrasib) tablet, coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0b8bf078-34c2-4f45-9012-38a8ac082b01. Date Accessed October 8, 2026.
KRAZATI (adagrasib) Prescribing Information. Bristol Myers Squibb. https://packageinserts.bms.com/pi/pi_krazati.pdf. Date Accessed October 8, 2026.
Withdrawn Cancer Accelerated Approvals. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals. Date Accessed October 8, 2026.